A Phase 2 interventional study of Lucitanib in Breast Cancer, Metastatic Breast Cancer and MBC, sponsored by Clovis Oncology, Inc.. Terminated at 33 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-23.
Sponsored by Clovis Oncology, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine whether lucitanib is safe and effective in the treatment of patients with FGF aberrant metastatic breast cancer, as well as in the treatment of patients with biomarker negative (FGF non-aberrant) metastatic breast cancer.
Lucitanib is a selective, orally available tyrosine kinase inhibitor targeting FGFR1-3, VEGFR1-3, and PDGFRα and β, with activity in relevant cell lines and animal models.
The first in human trial of lucitanib demonstrated that daily dosing with lucitanib can provide durable clinical responses in patients with FGFR1- or 11q (FGF3, FGF4, Cyclin D1, or FGF19)-amplified breast cancer. RECIST partial responses (PRs) were also observed in patients not known to have FGF abnormalities.
Based on these results, this study is designed to explore the safety and anti-tumor activity of daily lucitanib in breast cancer patients with and without alterations of the FGF pathway.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
This study's enrollment of 178 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Browse Breast Neoplasms studies →Clovis Oncology, Inc. is the lead sponsor of 14 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mg of lucitanib daily in patients with FGFR1-amplified or 11q-amplified metastatic breast cancer.
Drug: Lucitanib
15 mg of lucitanib daily in patients with FGFR1-amplified and 11q-amplified metastatic breast cancer.
Drug: Lucitanib
10 mg of lucitanib daily in patients with FGFR1 non-amplified and 11q non-amplified metastatic breast cancer.
Drug: Lucitanib
Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
Also known as: CO-3810
Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by the Investigator
The primary efficacy endpoint of PFS was calculated as 1+ the number of days from the date of first dose of study drug to disease progression or death due to any cause, whichever occurs first. Patients without a documented event of progression were censored on the date of their last adequate tumor assessment (i.e., radiologic assessment), or the date of randomization if no tumor assessments were performed. Progression events were determined by the investigator. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
Time frame: From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months
Objective Response Rate (ORR) by RECIST v1.1
ORR is the percentage of patients with a best response of CR or PR according to RECIST v1.1. The best response is recorded from the start of the treatment (Day 1) until disease progression or recurrence. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.
Time frame: From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months
Duration of Response (DR) by RECIST v1.1
DR for complete response (CR) and partial response (PR) was measured from the date that any of these best confirmed responses was first recorded until the first date that PD was objectively documented. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.
Time frame: From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months
Disease Control Rate (DCR) by RECIST v1.1
The DCR is defined as the percentage of patients with a best response rate of CR, PR, or SD for at least 12 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter since the treatment started.
Time frame: From Cycle 1 Day 1 until disease progression or end of treatment, whichever came first, assessed up to 29 months
Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - Cmax
The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. Cmax = maximum concentration following administration of lucitanib.
Time frame: Study Day -7 to Study Day 1, or approximately 8 days
Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - Tmax
The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. Tmax = time to maximum concentration following administration of lucitanib
Time frame: Study Day -7 to Study Day 1, or approximately 8 days
Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - AUClast
The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. AUClast = area under the plasma concentration time curve from time 0 to the last quantifiable time point (24 hour)
Time frame: Study Day -7 to Study Day 1, or approximately 8 days
Comparative Pharmacokinetics (PK) of the Lucitanib Capsule Formulation vs. Tablet Formulation - AUCinf
The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. AUCinf = area under the plasma concentration time curve from 0 to infinity
Time frame: Study Day -7 to Study Day 1, or approximately 8 days
Relative Bioavailability Analysis for Tablet vs Capsule - Cmax, AUClast, AUCinf
Relative bioavailability of lucitanib was evaluated by comparison of (log-transformed) AUClast, Cmax and AUCinf of the tablet formulation to the capsule formulation using an analysis of variance (ANOVA) model with treatment as a fixed effect. The geometric means, ratio of the geometric means and 90% confidence intervals (CI) on the ratio of Tablet to Capsule (T:R) were presented for AUClast, Cmax and AUCinf. The CIs on the ratio of untransformed PK parameters were derived through reverse transformation of the 90% CI of the difference in the log scale to the 90% CI of the ratio in the original scale.
Time frame: Study Day -7 to Study Day 1, or approximately 8 days
Overall Survival
Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death (due to any cause). Patients without a known date of death will be censored on the date the patient was last known to be alive.
Time frame: Cycle 1 Day 1 to date of death, assessed up to 29 months
Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Total Score
FACT-B is used for assessment of health-related quality of life (QoL) in participants with breast cancer. It consists of 37 items, summarized to 5 subscales: physical (7 items), functional (7 items), social/family (7 items); all 3 ranged from 0 to 28, emotional (6 items) ranging from 0 to 24, and breast cancer subscale (10 items) ranging from 0 to 40; high subscale score represents a better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. FACT-B Total Score is derived from adding the five subscale scores. Total possible score ranges from 0 to 148. High scale score represents a better QoL.
Time frame: From Cycle 1 Day 1 until end of treatment, assessed up to 29 months
178 patients were recruited from 32 sites in the United States.
| Milestone | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Started | 109 | 69 |
| Completed | 109 | 69 |
| Not completed | 0 | 0 |
The primary efficacy endpoint of PFS was calculated as 1+ the number of days from the date of first dose of study drug to disease progression or death due to any cause, whichever occurs first. Patients without a documented event of progression were censored on the date of their last adequate tumor assessment (i.e., radiologic assessment), or the date of randomization if no tumor assessments were performed. Progression events were determined by the investigator. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression.
| Days | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by the Investigator | 93 (78 to 140) | 77 (50 to 86) |
ORR is the percentage of patients with a best response of CR or PR according to RECIST v1.1. The best response is recorded from the start of the treatment (Day 1) until disease progression or recurrence. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.
| percentage of participants | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | All Patients |
|---|---|---|---|
| Objective Response Rate (ORR) by RECIST v1.1 | 4.7 | 1.5 | 3.5 |
DR for complete response (CR) and partial response (PR) was measured from the date that any of these best confirmed responses was first recorded until the first date that PD was objectively documented. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter.
| Days | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Duration of Response (DR) by RECIST v1.1 | 175 (44 to 209) | 336 (336 to 336) |
The DCR is defined as the percentage of patients with a best response rate of CR, PR, or SD for at least 12 weeks. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions, defined by and assessed as: Complete Response (CR), is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter. Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter since the treatment started.
| percentage of patients | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | All Patients |
|---|---|---|---|
| Disease Control Rate (DCR) by RECIST v1.1 | 48.1 | 34.3 | 42.8 |
The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. Cmax = maximum concentration following administration of lucitanib.
| ng/mL | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Tablet | 292 ± 156 | 278 ± 99.8 |
| Capsule | 265 ± 137 | 285 ± 121 |
The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. Tmax = time to maximum concentration following administration of lucitanib
| Hours | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Tablet | 1.0 (0.5 to 4.0) | 1.0 (0.5 to 2.5) |
| Capsule | 1.5 (1.0 to 4.0) | 1.0 (1.0 to 2.5) |
The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. AUClast = area under the plasma concentration time curve from time 0 to the last quantifiable time point (24 hour)
| h*ng/mL | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Tablet | 2550 ± 1150 | 2840 ± 1230 |
| Capsule | 2650 ± 1380 | 2420 ± 613 |
The comparative PK study was a within-patient comparison of tablet and capsule formulations of lucitanib administered orally. PK sampling was performed at specified time points on each of the following two days: • Day -7: patients received a single administration of 10 mg or 15 mg lucitanib tablet formulation • Day 1: patients received a single administration of 10 mg or 15 mg lucitanib in capsule formulation. AUCinf = area under the plasma concentration time curve from 0 to infinity
| h*ng/mL | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Tablet | 4780 ± 2140 | 5720 ± 3760 |
| Capsule | 5680 ± 2730 | 4620 ± 1620 |
Relative bioavailability of lucitanib was evaluated by comparison of (log-transformed) AUClast, Cmax and AUCinf of the tablet formulation to the capsule formulation using an analysis of variance (ANOVA) model with treatment as a fixed effect. The geometric means, ratio of the geometric means and 90% confidence intervals (CI) on the ratio of Tablet to Capsule (T:R) were presented for AUClast, Cmax and AUCinf. The CIs on the ratio of untransformed PK parameters were derived through reverse transformation of the 90% CI of the difference in the log scale to the 90% CI of the ratio in the original scale.
| Percentage (tablet/capsule) | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Cmax Geometric Mean Ratio | 111.73 (70.35 to 177.45) | 100.56 (64.59 to 156.55) |
| AUClast Geometric Mean Ratio | 97.58 (60.61 to 157.09) | 112.2 (78.73 to 159.89) |
| AUCinf Geometric Mean Ratio | 82.9 (51.75 to 132.81) | 114.23 (70.09 to 186.15) |
Overall survival (OS) is defined as the number of days from the date of first dose of study drug to the date of death (due to any cause). Patients without a known date of death will be censored on the date the patient was last known to be alive.
| Months | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | All Patients |
|---|---|---|---|
| Overall Survival | 15.0 (10.7 to 17.3) | 7.7 (6.1 to 10.3) | 10.7 (8.5 to 13.7) |
FACT-B is used for assessment of health-related quality of life (QoL) in participants with breast cancer. It consists of 37 items, summarized to 5 subscales: physical (7 items), functional (7 items), social/family (7 items); all 3 ranged from 0 to 28, emotional (6 items) ranging from 0 to 24, and breast cancer subscale (10 items) ranging from 0 to 40; high subscale score represents a better QoL. All single-item measures range from 0='Not at all' to 4='Very much'. FACT-B Total Score is derived from adding the five subscale scores. Total possible score ranges from 0 to 148. High scale score represents a better QoL.
| units on a scale | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | All Patients |
|---|---|---|---|
| Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B) Total Score | -2.422 ± 15.5134 | -7.586 ± 17.0709 | -4.307 ± 16.2248 |
Collected over Adverse events were reported from the time of first dose of lucitanib through 28 days after last dose protocol-specified treatment administration, up to approximately 30 months. In addition, study procedure-related AEs that occur after signing of the informed consent form and before administration of lucitanib were also collected.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lucitanib (CO-3810) 10 mg QD | 5/109 (4.6%) | 31/109 (28.4%) | 107/109 (98.2%) |
| Lucitanib (CO-3810) 15 mg QD | 7/69 (10.1%) | 22/69 (31.9%) | 69/69 (100%) |
| Event | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/109 | 5/69 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/109 | 3/69 |
| NauseaGastrointestinal disorders | 1/109 | 2/69 |
| VomitingGastrointestinal disorders | 0/109 | 2/69 |
| HypertensionVascular disorders | 2/109 | 2/69 |
| HyponatraemiaMetabolism and nutrition disorders | 3/109 | 1/69 |
| DysphagiaGastrointestinal disorders | 2/109 | 0/69 |
| PneumoniaInfections and infestations | 2/109 | 1/69 |
| HeadacheNervous system disorders | 2/109 | 0/69 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/109 | 1/69 |
| Event | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD |
|---|---|---|
| HypertensionVascular disorders | 85/109 | 50/69 |
| FatigueGeneral disorders | 55/109 | 37/69 |
| HypothyroidismEndocrine disorders | 41/109 | 34/69 |
| NauseaGastrointestinal disorders | 53/109 | 33/69 |
| HeadacheNervous system disorders | 42/109 | 24/69 |
| VomitingGastrointestinal disorders | 35/109 | 24/69 |
| Decreased appetiteMetabolism and nutrition disorders | 36/109 | 21/69 |
| ProteinuriaRenal and urinary disorders | 22/109 | 22/69 |
| DiarrhoeaGastrointestinal disorders | 33/109 | 19/69 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 22/109 | 14/69 |
| Age, Continuous(years) | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | Total |
|---|---|---|---|
| Median | 57.0 (27 to 82) | 53.0 (27 to 80) | 55.0 (27 to 82) |
| Sex: Female, Male(Participants) | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | Total |
|---|---|---|---|
| Female | 109 | 67 | 176 |
| Male | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | Total |
|---|---|---|---|
| White | 87 | 61 | 148 |
| Asian | 5 | 3 | 8 |
| Black | 10 | 1 | 11 |
| Not provided | 4 | 3 | 7 |
| Unknown/Not assessed | 2 | 1 | 3 |
| Other | 1 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | Total |
|---|---|---|---|
| Hispanic or Latino | 8 | 6 | 14 |
| Not Hispanic or Latino | 97 | 61 | 158 |
| Not Provided | 4 | 2 | 6 |
| Number of Prior Anticancer Therapies(Therapies) | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | Total |
|---|---|---|---|
| Median | 6.0 (1 to 18) | 6.0 (1 to 16) | 6.0 (1 to 18) |
| Fibroblast Growth Factor (FGF) Status(Participants) | Lucitanib (CO-3810) 10 mg QD | Lucitanib (CO-3810) 15 mg QD | Total |
|---|---|---|---|
| 11q | 34 | 25 | 59 |
| FGFR1 | 50 | 28 | 78 |
| FGFR1 & 11q | 18 | 10 | 28 |
| Negative | 7 | 6 | 13 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2014 to primary completion in Jan 2017, 28 months.
Results were first posted in Jun 2020, 3 years 5 months after primary completion. A results delay was requested in Aug 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: E-3810
Clovis Oncology, Inc.